Cowealth Medical Holding Co Ltd (4745) Fair Value & Analysis
Healthcare · TW · Market cap 894M TWD
Strengths
Risks
Fair value as of: Aug 13, 2026
From 8 valuation models · updated 11 days ago
Fair value updated Aug 13, 2026, revised from 14.28 TWD to 14.26 TWD (−0.1%) since Jul 23, 2026. Share price −11.2% over the past month.
Below-average quality, trading 16% below our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price is below even our cautious bear case (14.23 TWD). The market is more pessimistic than our downside scenario.
- The models converge in a tight band (14.23 TWD to 14.33 TWD), unusually little disagreement for a valuation.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range 10.90 TWD – 34.40 TWD · fair‑value band 14.23 TWD – 14.33 TWD · the 11.95 TWD price screens below the 14.26 TWD fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Cowealth Medical Holding Co Ltd (4745) currently trades at 11.95 TWD, while our model-based Fair Value estimate is 14.26 TWD, implying the stock looks roughly 19.3% undervalued today. The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Cowealth Medical Holding Co Ltd generated revenue of 2.9B TWD at a net margin of -8.6%. Revenue declined 11.6% year over year. It earns a return on equity of -6.5%. Net debt stands at 60.9M TWD. Fundamentals as of Aug 13, 2026
Our scenario range runs from 14.23 TWD (bear case) to 14.33 TWD (bull case); at 11.95 TWD, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 56% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -28% fair-value upside, at 19%, 4745 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 8 models by family
Widest divergence: Asset-Based (29.04 TWD) versus Dividend Discount (3.92 TWD). Highest evidence: Growth DCF (80).
Notify me when 4745 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 38 · Market factors (momentum, volatility) 25
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Cowealth Medical Holding Co., Ltd., together with its subsidiaries, engages in trading of medical equipment, reagents, and spare parts in Taiwan, China, and Hong Kong. It operates in two segments, Sells Equipment, and Sells Reagents and Others.
Full company description
Cowealth Medical Holding Co., Ltd., together with its subsidiaries, engages in trading of medical equipment, reagents, and spare parts in Taiwan, China, and Hong Kong. It operates in two segments, Sells Equipment, and Sells Reagents and Others. The company also offers acme empowerment program, including al-assisted clinical decision support system, platform of management analysis and decision making, multi-channel coaxial-time-audio-video-image digital platform for operating rooms, and cross-trait medical resource platform. In addition, it provides equipment comprising CyberKnife Stereotactic Radiosurgery System, a non-invasive treatment alternative for cancerous and non-cancerous tumors, as well as other medical conditions requiring radiation therapy; LipiView Ocular Surface Interferometer and LipiView Thermal Pulsation System, a system designed to diagnose and address meibomian gland dysfunction; and MRIdian-Linac, an MRI-guided radiation therapy system. Further, the company is involved in general investing; import and export medical equipment, reagents, and spare parts; nutrition, health, and social and economic consulting business; software development, IT equipment maintenance, and IT system maintenance service; and hospital and business management. Cowealth Medical Holding Co., Ltd. was founded in 1997 and is based in George Town, Cayman Islands.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Cowealth Medical Holding Co Ltd reported revenue of 3.0B TWD in FY2025 versus 5.1B TWD in FY2021, a compound −12.9%/yr. Reported net income was −247M TWD in FY2025.
Watch 4745: get an alert when its fair value changes →
Peer Group
Medical Devices · 362 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $110.91 | $74.79 | -33% |
| Stryker Corporation SYK | $327.70 | $186.28 | -43% |
| Medtronic plc MDT | $90.76 | $65.57 | -28% |
| Boston Scientific Corporation BSX | $50.37 | $38.44 | -24% |
| Edwards Lifesciences Corporation EW | $93.05 | $41.02 | -56% |
| Siemens Healthineers AG SHL | €39.04 | €33.87 | -13% |
| DexCom, Inc DXCM | $90.80 | $38.95 | -57% |
| GE HealthCare Technologies Inc GEHC | $74.82 | $64.13 | -14% |
| Koninklijke Philips N.V PHIA | €23.69 | €14.36 | -39% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥150.63 | ¥147.63 | -2% |
Compare Cowealth Medical Holding Co Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Cowealth Medical Holding Co Ltd (4745) overvalued or undervalued?
What is the fair value of 4745?
What is the quality score of 4745?
What is the revenue of Cowealth Medical Holding Co Ltd (4745)?
What is the net profit margin of 4745?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Cowealth Medical Holding Co Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.